Table 2.
ANGPTL8 concentration in diseases.
| Diseases | ANGPTL8 concentration change | Kits manufacturer |
|---|---|---|
| T1DM | ↑(28, 29) | EIAAB |
| T2DM | ↑(21, 29–33, 35, 37) | EIAAB |
| ↑(34, 36) | Phoenix | |
| ↓(38) | Cusabio | |
| –(39) | EIAAB | |
| –(40) | Aviscera | |
| Obesity | ↑(22) | EIAAB |
| ↑(36) | Phoenix | |
| ↓(38, 42, 43) | Cusabio | |
| –(40) | Aviscera | |
| MS | ↑(19) | EIAAB |
| ↓(44) | Cusabio | |
| NAFLD | ↑(45) | Phoenix |
| Pregnancy | ↑(27, 46) | EIAAB |
| GDM | ↓(27) | EIAAB |
| ↑(46) | EIAAB | |
| ↑(47) | USCN Life | |
| ↑(48) | Phoenix | |
| PCOS | ↑(10) | Cusabio |
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; MS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; GDM, gestational diabetes mellitus; PCOS, polycystic ovary syndrome.